Detalhe da pesquisa
1.
Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study.
Clin Appl Thromb Hemost
; 30: 10760296241241525, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38523315